The European Medicines Agency's committee has recommended approval of French drugmaker Sanofi's first-of-its-kind drug that ...
Regulators upheld their earlier decision after reexamination, saying the substance does not meet the criteria for new active ...
The recommendation follows results showing markedly longer time to diagnosis of stage 3 T1D in treated patients, a condition ...
The inequitable distribution of vaccines during the COVID-19 pandemic was the final proof of the need for more home-grown ...
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II ...
During a meeting this week, an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed 10 new ...
Shortly after crossing the FDA’s finish line, Ionis Pharmaceuticals’ RNA-targeted hereditary angioedema (HAE) treatment ...
1don MSNOpinion
Anavex tumbles as Alzheimer’s therapy faces EU rejection
Anavex Life Sciences (AVXL) stock falls as the company faces a potential failure to win EU approval for its Alzheimer’s ...
Scholar Rock soared by 24.41 percent on Friday to close at $37.41 apiece as investor sentiment was boosted by the progress of ...
Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and ...
Anavex Life Sciences said European regulators informed it of a negative trend vote related to its application for its blarcamesine treatment of early Alzheimer's disease. The Committee for Medicinal ...
EMA’s PRIME designation bolsters Neurona’s global development strategy and underscores the company’s commitment to bringing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback